Menu

Top Stories

Gordon L. Snider Critical Issues Workshop to focus on the COPD National Action Plan and Alpha-1

Gordon L. Snider Critical Issues Workshop to focus on the COPD National Action Plan and Alpha-1
Wednesday, November 14, 2018
The 17th Gordon L. Snider Critical Issues Workshop, titled “The Alpha-1 Foundation Approach to the COPD National Action Plan” is being held on November 15th, 2018, in New York, NY, and includes expert representation from academia, industry, the National Institutes of Health (NIH), and patients to focus on the 2017 COPD National Action Plan and Alpha-1 Antitrypsin Deficiency...
Divider

Papers on Alpha-1 research published in the COPD Foundation Journal

Wednesday, November 7, 2018
The latest issue of the Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation (Volume 5, Issue 4 – 2018) features papers from presenters at the “3rd Biennial International Research Conference on Alpha-1...
Divider

Mereo BioPharma and TAP work together in clinical study

Tuesday, November 6, 2018
Mereo BioPharma Group plc announced a collaboration with (and investment from) the venture philanthropy arm of the Alpha-1 Foundation, The Alpha-1 Project, Inc. (TAP) in Mereo’s MPH-966 development program. MPH-966 is an oral neutrophil...
Divider

2018 research grants on Alpha-1 awarded

Tuesday, May 22, 2018
At a cocktail reception the evening of May 21st, held at The Prado at Balboa Park, within the framework of the American Thoracic Society (ATS) 2018 International Conference in San Diego, California, the Alpha-1 Foundation (A1F) announced the...
Divider

Alpha Jonathan Maidment hikes the Pacific Crest Trail

Thursday, May 17, 2018
This story appears in the Spring 2018 issue of Alpha-1-To-One Magazine. Subscriptions are free. Determined and driven are the first two adjectives that come to mind when you get a grasp of the endeavor that 23-year old Jonathan Maidment has...
Divider

First John W. Walsh Translational Research Award granted

Wednesday, January 31, 2018
MIAMI/BOSTON, January 31, 2018 – The Alpha-1 Foundation celebrates the first granting of the John W. Walsh Translational Research Award in Alpha-1 Antitrypsin Deficiency, an honorable award named after John W. Walsh, co-founder of the...
Divider

Alpha-1 gene therapy trial doses first patient, recruitment continues

Thursday, January 11, 2018
Adverum Biotechnologies, a clinical-stage gene therapy company targeting unmet medical needs in several diseases, is recruiting patients for a clinical trial for Alpha-1 Antitrypsin (A1AT) Deficiency, designed to evaluate the safety and protein...
Divider

Spark Therapeutics explores payment options after revealing price tag for first gene therapy in the US

Thursday, January 4, 2018
Philadelphia based pharmaceutical company, Spark Therapeutics, confirmed conversations with the U.S. Centers of Medicare and Medicaid Services on a proposal that would allow for multi-year payment plans for its innovative treatment, Luxturna, the...
Divider

ATS renames PAR Excellence Award after John W. Walsh

Wednesday, December 13, 2017
The American Thoracic Society (ATS) Public Advisory Roundtable was moved to rename the annual PAR Excellence Award by a unanimous vote in November. The award, presented at the ATS International Conference, will now be referred to as the...
Divider

Alpha-1 research pioneer Jack A. Pierce, MD, passes away

Thursday, December 7, 2017
“One of the early investigators of Alpha–1 and the initial head of the one of the first Pulmonary and Critical Care departments in the country at Washington University in St. Louis has died at the age of 92. I believe few of...
Divider

Recruitment begins for gene therapy clinical trial for Alpha-1 Antitrypsin Deficiency

Tuesday, December 5, 2017
Enrollment for a trial for a new treatment for Alpha–1 related lung disease begins today. Adverum Biotechnologies, in partnership with the Alpha–1 Foundation will be recruiting patients, as well as healthy ZZ and Znull...
Divider

Your helping hand has an impact for Alphas worldwide

Friday, December 1, 2017
When you donate to the Alpha–1 Foundation, you are helping Alphas everywhere by providing support services to newly diagnosed adults and children, giving access to education to both Alphas and medical professionals, allowing for family...
Divider

UK company acquires license for a potential pill-based Alpha–1 lung therapy

Wednesday, November 1, 2017
Mereo BioPharma Group, a clinical stage, UK-based, biopharmaceutical company focused on rare and specialty diseases, announced that it has reached an agreement with AstraZeneca for an exclusive license, including an option to acquire, AZD9668, an...
Divider
123456789

Article Search

Enter keywords in text box and click Search button for results.